The University of Southampton
University of Southampton Institutional Repository

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
In the last 20 years, noninvasive serum biomarkers to identify liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) have been developed, validated against liver biopsy (the gold standard for determining the presence of liver fibrosis) and made available for clinicians to use to identify ≥F3 liver fibrosis. The aim of this review is firstly to focus on the current use of widely available biomarkers and their performance for identifying ≥F3. Secondly, we discuss whether noninvasive biomarkers have a role in identifying F2, a stage
of fibrosis that is now known to be a risk factor for cirrhosis and overall mortality. We also consider whether machine learning algorithms offer a better alternative for identifying individuals with ≥F2 fibrosis. Thirdly, we summarise the utility of noninvasive serum biomarkers for predicting liver related outcomes (e.g. ascites and hepatocellular carcinoma) and non-liver related outcomes (e.g. cardiovascular-related mortality and extra hepatic cancers). Finally, we examine whether serial measurement of biomarkers can be used to monitor liver disease, and whether the use of noninvasive biomarkers in drug trials for non-alcoholic steatohepatitis (NASH) can accurately, (compared to liver histology), monitor liver fibrosis progression/regression. We conclude by offering our perspective on the future of serum biomarkers for the detection and monitoring of liver fibrosis in NAFLD.
NAFLD: non-alcoholic fatty liver disease, Noninvasive serum biomarkers, Liver fibrosis
2287-285X
S157-S170
Reinson, Tina
929fcf68-3a7d-42e4-9efd-e9d188b2b9c8
Buchanan, Ryan Malcolm
a092c890-492a-478f-8d13-0453d482a700
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Reinson, Tina
929fcf68-3a7d-42e4-9efd-e9d188b2b9c8
Buchanan, Ryan Malcolm
a092c890-492a-478f-8d13-0453d482a700
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c

Reinson, Tina, Buchanan, Ryan Malcolm and Byrne, Christopher (2022) Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future. Clinical and Molecular Hepatology, 29(Suppl), S157-S170, [CMH-2022-0348.R1].

Record type: Article

Abstract

In the last 20 years, noninvasive serum biomarkers to identify liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) have been developed, validated against liver biopsy (the gold standard for determining the presence of liver fibrosis) and made available for clinicians to use to identify ≥F3 liver fibrosis. The aim of this review is firstly to focus on the current use of widely available biomarkers and their performance for identifying ≥F3. Secondly, we discuss whether noninvasive biomarkers have a role in identifying F2, a stage
of fibrosis that is now known to be a risk factor for cirrhosis and overall mortality. We also consider whether machine learning algorithms offer a better alternative for identifying individuals with ≥F2 fibrosis. Thirdly, we summarise the utility of noninvasive serum biomarkers for predicting liver related outcomes (e.g. ascites and hepatocellular carcinoma) and non-liver related outcomes (e.g. cardiovascular-related mortality and extra hepatic cancers). Finally, we examine whether serial measurement of biomarkers can be used to monitor liver disease, and whether the use of noninvasive biomarkers in drug trials for non-alcoholic steatohepatitis (NASH) can accurately, (compared to liver histology), monitor liver fibrosis progression/regression. We conclude by offering our perspective on the future of serum biomarkers for the detection and monitoring of liver fibrosis in NAFLD.

Text
ReviewPaperCMH_NonInvasiveSerumBiomarkers_ReviewFinal_V2.6_EndnoteDisabled_Accepted_21112022 - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (636kB)
Text
SupplementaryInformation_21112022_Accepted - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (244kB)

More information

Accepted/In Press date: 21 November 2022
e-pub ahead of print date: 22 November 2022
Published date: 22 November 2022
Keywords: NAFLD: non-alcoholic fatty liver disease, Noninvasive serum biomarkers, Liver fibrosis

Identifiers

Local EPrints ID: 471919
URI: http://eprints.soton.ac.uk/id/eprint/471919
ISSN: 2287-285X
PURE UUID: e51bb06d-291b-4c56-bbb7-40829a299f8e
ORCID for Tina Reinson: ORCID iD orcid.org/0000-0002-2436-1906
ORCID for Christopher Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 22 Nov 2022 17:45
Last modified: 17 Mar 2024 04:04

Export record

Contributors

Author: Tina Reinson ORCID iD
Author: Ryan Malcolm Buchanan

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×